Janssen-Cilag International NV, a Johnson & Johnson company, announced three-year follow-up data from the Phase 3 CARTITUDE-4 study ...
Johnson & Johnson's recent studies reveal impressive response rates for Talvey in combination with Tecvayli and other ...
2h
Johnson & Johnson (JNJ) announced results from the Phase 3 CEPHEUS study demonstrating a significant clinical improvement with ...
Investor's Business Daily on MSN12h
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple MyelomaLegend Biotech said Friday its cancer drug, Carvykti, lowered the risk of death by 45% in a study of multiple myeloma patients.
Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, ...
HDP-101, a novel antibody-drug conjugate, targets BCMA with a synthetic amanitin payload that causes tumor cell death.
April's vote of the FDA Oncology Drug Advisory Committee to support use of MRD-negative CR as an end point for accelerated ...
Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...
Multiple myeloma patients with COVID-19 have high rates of hospitalization, ICU admission, and death, according to researchers.
Patti Scialfa, Bruce Springsteen’s wife, recently shared that she was diagnosed in 2018 with a type of blood cancer known as ...
The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's ...
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the phase 3 CEPHEUS trial of daratumumab with bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback